Home › Targets › RAS

RAS (4 companies · 11 programs)

Companies with an active program directed at RAS.

Revolution Medicines, Inc. RVMD

RASONQUE — Pancreatic Ductal Adenocarcinoma Approved
RASONQUE — Non-Small Cell Lung Cancer NDA Submitted
RMC-5127 Phase 1
RM-055

BridgeBio Oncology Therapeutics, Inc. BBOT

BBO-10203 — Colorectal Cancer Phase 1
BBO-10203 — Non-Small Cell Lung Cancer Phase 1
BBO-10203 — Pancreatic Ductal Adenocarcinoma Phase 1

ONCOLYTICS BIOTECH INC ONCY

pelareorep — Pancreatic Ductal Adenocarcinoma Phase 2
pelareorep — Squamous Cell Carcinoma of the Anal Canal Phase 1
pelareorep — Metastatic Colorectal Cancer Phase 2

Erasca, Inc. ERAS

ERAS-0015 — Solid Tumors Phase 1